Continuing isatuximab treatment for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study allows people with multiple myeloma who are already benefiting from the drug isatuximab in an earlier clinical trial to keep receiving it after that trial ends. It is an extension study, meaning you can continue your treatment without interruption.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have been in a previous isatuximab clinical trial and completed all its requirements.
- You must still be receiving isatuximab (or be able to get it locally) and your doctor must confirm you are still benefiting from it.
- If you are a woman who can become pregnant, you must not be pregnant or breastfeeding and must agree to use two forms of birth control. Men must agree not to donate sperm.
- You must not have signs that your cancer is getting worse during the previous trial.
- You must have recovered from any serious side effects of your previous cancer treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests isatuximab (an anti-cancer antibody) combined with other study medicines in people whose multiple myeloma has come back or not responded. It aims to improve control of the disease after you’ve already had multiple prior treatments.
This trial tests a new combination of drugs (isatuximab, carfilzomib, and dexamethasone) given as shots under the skin for people whose multiple myeloma has come back or stopped responding to treatment. It aims to see if this mix works better than previous options.
This trial tests a combination of two drugs—elranatamab and isatuximab—for people with multiple myeloma that has come back or stopped responding to at least two prior treatments. The goal is to see if this new combination can help control the disease.
This Phase 2 study tests whether adding isatuximab and lenalidomide after an autologous stem cell transplant can keep multiple myeloma from coming back when tests show leftover (minimal) disease. If it works, it may improve how long you stay in response.
This trial offers continued access to elranatamab for people with multiple myeloma who were already benefiting from it in a previous study and whose earlier study ended.
This study tests a combination of three drugs (isatuximab, dexamethasone, and lenalidomide) given at a slow, gentle pace for people with multiple myeloma who are considered very frail. The goal is to see if this gentler approach works well and is safe for those who may not tolerate stronger treatments.
Hear when a new Plasma Cell Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.